Charov K, Burkart M
ACS Infect Dis. 2019; 5(9):1518-1523.
PMID: 31317739
PMC: 7607843.
DOI: 10.1021/acsinfecdis.9b00150.
Markvicheva E, Tkachuk N, Kuptsova S, Dugina T, Strukova S, Kirsh YuE
Appl Biochem Biotechnol. 1996; 61(1-2):75-84.
PMID: 9100346
DOI: 10.1007/BF02785690.
Grand R, Turnell A, Grabham P
Biochem J. 1996; 313 ( Pt 2):353-68.
PMID: 8573065
PMC: 1216916.
DOI: 10.1042/bj3130353.
Whinna H, Church F
J Protein Chem. 1993; 12(6):677-88.
PMID: 8136018
DOI: 10.1007/BF01024926.
HALL W, Ganguly P
J Cell Biol. 1980; 85(1):70-82.
PMID: 7364876
PMC: 2110594.
DOI: 10.1083/jcb.85.1.70.
Significance of cross-linking of alpha 2-plasmin inhibitor to fibrin in inhibition of fibrinolysis and in hemostasis.
Sakata Y, Aoki N
J Clin Invest. 1982; 69(3):536-42.
PMID: 7199538
PMC: 371009.
DOI: 10.1172/jci110479.
"Fibrinogen Tokyo II". An abnormal fibrinogen with an impaired polymerization site on the aligned DD domain of fibrin molecules.
Matsuda M, Baba M, Morimoto K, Nakamikawa C
J Clin Invest. 1983; 72(3):1034-41.
PMID: 6886002
PMC: 1129270.
DOI: 10.1172/JCI111027.
Identification of a congenital dysthrombin, thrombin Quick.
Henriksen R, Owen W, Nesheim M, Mann K
J Clin Invest. 1980; 66(5):934-40.
PMID: 6776145
PMC: 371528.
DOI: 10.1172/JCI109961.
Cross-linking of alpha 2-plasmin inhibitor to fibrin by fibrin-stabilizing factor.
Sakata Y, Aoki N
J Clin Invest. 1980; 65(2):290-7.
PMID: 6444305
PMC: 371366.
DOI: 10.1172/JCI109671.
Binding of thrombin to cultured human fibroblasts: evidence for receptor modulation.
HALL W, Ganguly P
J Cell Biol. 1980; 87(3 Pt 1):601-10.
PMID: 6257726
PMC: 2110770.
DOI: 10.1083/jcb.87.3.601.
Letter: Human chorionic gonadotropin: a proposal for the amino acid sequence.
Morgan F, Birken S, Canfield R
Mol Cell Biochem. 1973; 2(1):97-9.
PMID: 4797188
DOI: 10.1007/BF01738683.
Fibrinogen-fibrin conversion as determined by polymer bead sedimentation technique.
Exner T, KOPPEL J
Experientia. 1972; 28(12):1421-3.
PMID: 4654192
DOI: 10.1007/BF01957825.
Effect of selective proteolysis on the accumulation of 5-hydroxytryptamine by intact rat blood platelets.
Sneddon J, Williams K
Br J Pharmacol. 1974; 52(2):237-44.
PMID: 4451819
PMC: 1776881.
DOI: 10.1111/j.1476-5381.1974.tb09706.x.
Mechanisms of thrombin-induced modifications of human platelet cytoskeleton.
Sinigaglia F, Balduini C, Bisio A, Balduini C
Biochem J. 1985; 232(1):305-8.
PMID: 4084237
PMC: 1152877.
DOI: 10.1042/bj2320305.
Specificity of activated human protein C.
Stone S, Hofsteenge J
Biochem J. 1985; 230(2):497-502.
PMID: 3863616
PMC: 1152642.
DOI: 10.1042/bj2300497.
Effect of thrombomodulin on the kinetics of the interaction of thrombin with substrates and inhibitors.
Hofsteenge J, Taguchi H, Stone S
Biochem J. 1986; 237(1):243-51.
PMID: 3026312
PMC: 1146971.
DOI: 10.1042/bj2370243.
A gamma methionine-310 to threonine substitution and consequent N-glycosylation at gamma asparagine-308 identified in a congenital dysfibrinogenemia associated with posttraumatic bleeding, fibrinogen Asahi.
Yamazumi K, Shimura K, Terukina S, Takahashi N, Matsuda M
J Clin Invest. 1989; 83(5):1590-7.
PMID: 2496144
PMC: 303865.
DOI: 10.1172/JCI114056.
Release of alpha 2-plasmin inhibitor from plasma fibrin clots by activated coagulation factor XIII. Its effect on fibrinolysis.
Mimuro J, Kimura S, Aoki N
J Clin Invest. 1986; 77(3):1006-13.
PMID: 2419360
PMC: 423506.
DOI: 10.1172/JCI112352.
Fibrinogen Lima: a homozygous dysfibrinogen with an A alpha-arginine-141 to serine substitution associated with extra N-glycosylation at A alpha-asparagine-139. Impaired fibrin gel formation but normal fibrin-facilitated plasminogen activation....
Maekawa H, Yamazumi K, Muramatsu S, Kaneko M, Hirata H, Takahashi N
J Clin Invest. 1992; 90(1):67-76.
PMID: 1634621
PMC: 443064.
DOI: 10.1172/JCI115857.
Location of phosphatidylethanolamine and phosphatidylserine in the human platelet plasma membrane.
Schick P, Kurica K, Chacko G
J Clin Invest. 1976; 57(5):1221-6.
PMID: 1262468
PMC: 436775.
DOI: 10.1172/JCI108390.
